Proposed amendment provides for mandatory corrective measures before revocation of the suspension; suspension shall continue until the manufacturer undertakes corrective action. India proposes immediate suspension of manufacturing licences for NSQ drugs, with mandatory CAPA before revocation to ensure swift, accountable quality action. Draft amendments to India’s Drugs Rules would allow licensing authorities to immediately suspend manufacturers after a government analyst finds a medicine fails critical quality standards.